RecruitingPhase 2NCT06912633
Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)
Studying Retinitis pigmentosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- jCyte, Inc
- Principal Investigator
- Henry Klassen, MD, PhDjCyte, Inc
- Intervention
- human retinal progenitor cells(biological)
- Enrollment
- 60 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2025 – 2026
Study locations (14)
- Associated Retina Consultants, Phoenix, Arizona, United States
- California Retina Consultants, Bakersfield, California, United States
- Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
- Gavin Herbert Eye Institute, UC Irvine, Irvine, California, United States
- Retina Consultants Medical Group, Sacramento, California, United States
- Bay Area Retina Associates, Walnut Creek, California, United States
- Vitreo Retinal Associates, Gainesville, Florida, United States
- Georgia Retina, Marietta, Georgia, United States
- Illinois Retina Associates, Oak Park, Illinois, United States
- NJRetina, Teaneck, New Jersey, United States
- Long Island Vitreoretinal Consultants, Westbury, New York, United States
- Retina Consultants of Texas: Bellaire Retina Center, Bellaire, Texas, United States
- Retina Consultants of Texas: San Antonio, San Antonio, Texas, United States
- The Retina Group of Washington, Fairfax, Virginia, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06912633 on ClinicalTrials.govOther trials for Retinitis pigmentosa
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07502664Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)Ray Therapeutics, Inc.
- RECRUITINGNANCT07292987Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts HospitalCentre Hospitalier National d'Ophtalmologie des Quinze-Vingts
- RECRUITINGNANCT07266584Restoration of Central Vision With PRIMA in Patients With Photoreceptor DegenerationScience Corporation
- RECRUITINGNCT07228793Natural History Study of Patients With EYS-Associated RPSensor Technology for Deafblind
- RECRUITINGPHASE1, PHASE2NCT06891885A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis PigmentosaSumitomo Pharma America, Inc.
- RECRUITINGPHASE2NCT07174726A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis PigmentosaBeacon Therapeutics
- RECRUITINGPHASE2NCT06628947A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis PigmentosaKiora Pharmaceuticals, Inc.
- RECRUITINGNCT06982417InsightRP2 RegistryUniversity of Göttingen